MAGE-A family: attractive targets for cancer immunotherapy.
about
Dendritic cell-based cancer immunotherapy for colorectal cancerT-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies.Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases.High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinomaExpression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinomaInduction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcomaReplication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy.The role of molecular pathology in non-small-cell lung carcinoma-now and in the future.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma.MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.The Magea gene cluster regulates male germ cell apoptosis without affecting the fertility in micePotential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancerCorrelations between the MEG-A3 gene and incidence of breast cancer.Cancer Progression Prediction Using Gene Interaction Regularized Elastic Net.Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression.The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.An aptamer targeting shared tumor-specific peptide antigen of MAGE-A3 in multiple cancers.From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.CAR T-cell therapy: toxicity and the relevance of preclinical models.MAGE-A3: an immunogenic target used in clinical practice.Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene.Ing1 functions in DNA demethylation by directing Gadd45a to H3K4me3.Biochemical and proteomic characterization of retrovirus Gag based microparticles carrying melanoma antigens.Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic StressExpression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study.Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression.Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study.Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer.Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.Melanoma-associated antigen genes: a new trend to predict the prognosis of breast cancer patients.An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer.MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth.MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer.Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.Antibody response against cancer-testis antigens MAGEA4 and MAGEA10 in patients with melanoma.MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation.
P2860
Q26751339-9C203AAB-BA92-465A-8FF9-F78CB4153874Q30251555-4186969F-7681-406D-9365-AB4D8A2832C4Q33823065-B9E4578D-2829-4BA3-880E-88E7691E52EDQ34113528-FB4839F6-6101-4204-A453-8721E598CE73Q34340901-95BC32E9-03BC-42B3-9BCF-AC9FAC913F37Q34502094-1275DA52-C65F-41C5-9AD2-065D1DA2EA6EQ34786566-F496262B-115F-4E3C-9524-59799CFD7785Q35784865-242221F8-4F6E-4CC0-90EB-A5072D1ABD17Q36040599-AAAAF913-D58D-4F65-8CEC-6427118C11D9Q36637039-46E80AD4-AF8A-4C63-A933-7FB43EC19B47Q36782607-C9FAD93F-C456-4B89-8A1B-F9D67162D88AQ36796813-19B014D2-86C0-4625-A5D5-AFC791EB07B7Q36937284-26F091A6-2D39-4660-888C-65581D2F0BDFQ37392729-10C71817-071D-4786-9604-87DE34F8A200Q37582144-494ABFF2-BA83-4218-8F9C-C09839037F29Q37730783-FC16F767-8BC6-4736-86F9-E89FC448309FQ38064856-FD0A6036-EBD2-4442-8DFB-7385834E6DDAQ38216836-29C951DC-2A9A-4B0D-97A0-90529C056FFFQ38296833-1255CC3D-DBD3-43D2-9328-B2116CA51EF2Q38468283-9A3E3760-3249-4869-94B2-B881220087B8Q38525018-48E4E264-6C1F-41F0-9888-29D085713749Q38534721-54E0D948-BA01-4E40-A2F2-CE5AA2FABFA5Q39161562-463ACBCA-CA89-4055-8B06-152575102B6AQ39168529-42D2D228-E089-4C4E-B7C3-0BBD1B223128Q39198445-591AA32A-0D88-4BE3-8C99-BB6B3CA3BF53Q39610714-8C295319-FCC4-4B59-AEF6-D0730E6B795EQ40430454-DB523AFE-F6B9-4C8A-983E-8684249CEECBQ40977475-075820D6-6505-41B3-B1B2-B029D062D52FQ42366622-1F02C366-B656-4A80-8040-79ADFA81907BQ43635483-81A40684-A8CC-4F18-9181-53C4735038EDQ44294653-CC9E2E2F-A009-4348-9AE9-7EF67B4EB899Q45891499-5AF44A4E-F50F-4FD9-A9C4-D477C164D264Q46727790-3ECD229C-7B3B-41CF-86B0-AFF10BC04736Q47675838-4A955FDA-BC29-4798-BBFF-1D0E6D872710Q48030870-2A183DCD-6500-45DE-8553-3559C70D8140Q49278213-B69C08D1-E243-428F-8067-325B4A42CAC4Q50070846-B89BBCED-8AF2-4AC4-B0A8-7898D2CBF987Q51263170-EB58903D-C2EF-41AF-8E4A-5ED71249BD32Q55241840-6EC83631-C45B-402C-9E73-0AA4C036E9C0Q55242409-EAECEA0C-6164-475D-89AE-4ABA202A0A7C
P2860
MAGE-A family: attractive targets for cancer immunotherapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MAGE-A family: attractive targets for cancer immunotherapy.
@ast
MAGE-A family: attractive targets for cancer immunotherapy.
@en
MAGE-A family: attractive targets for cancer immunotherapy.
@nl
type
label
MAGE-A family: attractive targets for cancer immunotherapy.
@ast
MAGE-A family: attractive targets for cancer immunotherapy.
@en
MAGE-A family: attractive targets for cancer immunotherapy.
@nl
prefLabel
MAGE-A family: attractive targets for cancer immunotherapy.
@ast
MAGE-A family: attractive targets for cancer immunotherapy.
@en
MAGE-A family: attractive targets for cancer immunotherapy.
@nl
P2093
P1433
P1476
MAGE-A family: attractive targets for cancer immunotherapy.
@en
P2093
Baoen Shan
Meixiang Sang
Xinliang Zhou
Yishui Lian
P304
P356
10.1016/J.VACCINE.2011.09.014
P407
P577
2011-09-18T00:00:00Z